What is Atreca, Inc. (BCEL)?

Atreca, Inc. (BCEL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BCEL?

The current price of BCEL is $0.09. Prices are updated in real time on Stocks360.

What is BCEL's price-to-earnings (PE) ratio?

BCEL's trailing twelve-month PE ratio is -0.04, based on current price and earnings per share data available on Stocks360.

What is BCEL's market capitalization?

BCEL's market capitalization is $3,568,788.00, placing it in the small-cap tier.

Atreca, Inc. (BCEL)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.09

Market Cap

$3.57M

PE (TTM)

-0.04

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.03

Day Range

$0.09 – $0.09

52-wk Range

$0.05 – $1.20

Avg Volume

N/A

Volume

122.11K

Atreca, Inc. (BCEL) is a publicly traded company in the Healthcare sector. Latest price: $0.09. Market cap $3.57M. Trailing PE -0.04. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 13, 2023

EPS $-0.39 vs est. $-0.38

Missed by $0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Atreca, Inc.

Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.04×
P/S (TTM)	4.63×
P/B	0.04×
P/FCF (TTM)	-0.04×
EV / EBITDA	-0.40×
EV / Sales	47.56×
Earnings Yield	-2797.13%
Free Cash Flow Yield	-2286.66%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$36.62M
Revenue (TTM)	$770.00K
Net Income (TTM)	-$99.82M
Free Cash Flow (TTM)	-$81.61M
Net Debt	$33.06M
Working Capital	$61.73M
Gross Margin	-819.61%
Operating Margin	-12665.58%
Net Margin	-12617.79%
Return on Equity	-83.28%
Return on Invested Capital	-68.54%